To study the effect of weight loss and subsequent weight maintenance or weight regain on the activities of FVII and plasminogen activator inhibitor 1 (PAI-1) and the concentration of ®brinogen over 12 months in obese women consuming a hypoenergetic, low-fat diet with or without orlistat. In addition, the relation between the changes of the activities of PAI-1 and FVII with the changes of other cardiovascular risk factors were examined. METHODS AND PROCEDURES: Design Ð a 12-month randomized double-blind weight reduction trial of placebo and orlistat. Subjects Ð 51 healthy obese women (age 44 AE 0.7 y, BMI 36.2 AE 0.5 kgam 2 , mean AE s.e.m.) Treatment Ð the participants were on a hypoenergetic diet ( ± 600 kcal daily). The diet was adjusted for actual body weight ( ± 300 kcal) at 6 months. Women were randomized to receive either orlistat 120 mg three times daily (n 25) or placebo three times daily (n 26) for 12 months according to a double-blind protocol after a 1 month run-in period. Measurements Ð changes of body weight, body composition, haemostatic and other cardiovascular risk factors were measured at 3 ± 6 month intervals. The activity of plasma PAI-1 was measured by a chromogenic method, ®brinogen by the PT-derived method and the activity of FVII by the one-stage method. RESULTS: The changes in body weight between orlistat and placebo groups were not statistically signi®cantly different. Orlistat did not in¯uence haemostatic factors beyond its effect on weight loss. Therefore, the results of the orlistat and placebo groups were pooled. The average weight loss at 3, 6 and 12 months was 7.6, 9.5 and 10.0 kg, respectively (P`0.001). Between 6 and 12 months, 35% of women regained weight, 24% had stable weight and 41% continued to lose weight. No changes in the mean plasma ®brinogen concentration were observed at any time point during the trial. During the ®rst 3 months the activities of PAI-1 and FVII decreased. The decline depended on the magnitude of weight loss. Between months 6 and 12 the changes of PAI-1 and FVII activities paralleled the changes of body weight. The activities rose with weight rebound but remained below the 6-month values if weight loss was sustained or continued. The changes of serum insulin were signi®cantly correlated with the changes of both PAI-1 and FVII at 6 months and with PAI-1 at 12 months. CONCLUSIONS: The maintenance of modest weight loss is associated with long-term bene®ts in PAI-1 and FVII in obese women. The change of serum insulin is associated with the changes of PAI-1 activities. Fibrinogen is not affected by modest weight loss.
Introduction
Obese individuals have an increased risk of coronary heart disease (CHD). 1, 2 This may be explained by an unfavourable lipid pro®le, hyperinsulinaemia, elevated blood pressure, and also by increased blood coagulability and impaired endogenous ®brinolysis. Previous studies have shown that the activities of factor VII (FVIIc) and plasminogen activator inhibitor 1 (PAI-1) and the concentration of ®brinogen may rise with increasing body weight. 3 ± 5 The reported effects of weight reduction on FVIIc and ®brinogen are variable. 6 ± 8 Weight loss seems to lower PAI-1 activity, but the relation to the magnitude of weight reduction is unknown. Also, it is still unclear whether the improved ®brinolysis and decreased coagulation achieved by weight loss are maintained after weight stabilization and what happens with weight rebound. 8 ± 11 It has been suggested that initial improvements may disappear during weight maintenance. 8 We evaluated the impact of weight loss, weight maintenance and weight regain on the concentration of ®brinogen and the activities of FVII and PAI-1 during a 12-month clinical weight reduction trial and compared the changes of these haemostatic risk factors with concomitant changes of other cardiovascular risk factors.
Subjects and methods

Subjects
Fifty-®ve obese Finnish women (age 44 AE 0.7 y, BMI 36.2 AE 0.5 kgam 2 , mean AE s.e.m.) participated in a weightreduction programme using a hypoenergetic, low-fat diet with or without orlistat. The study was completed by 51 of the women. All subjects were healthy as established by physical examination, medical history and routine laboratory tests. Thirty-seven of women were non-smokers and 14 were smokers. Written consent was obtained from all subjects after a detailed explanation of the study protocol. The study was approved by the Ethical Committees of the Helsinki University Central Hospital and the University of Kuopio.
Experimental design
After a 4-week run in-period with a hypoenergetic ( ± 600 kcal daily, corrected for daily activities) diet the subjects were randomized to receive either orlistat 120 mg three times daily or placebo with the hypoenergetic diet. The diet was nutritionally balanced and hypocaloric designed to cause a weight loss of 0.25 ± 0.5 kgaweek, with 30% of calories as fat, 50% as carbohydrate, 20% as protein and a maximum of 300 mgaday cholesterol, and distributed into three main meals with a low-fat snack, if desired. Alcohol consumption was limited to be no more than 150 g of alcohol per week. The caloric intake was reduced by additional 300 kcaladay to compensate for the reduced energy requirements following weight loss at 6 months. Compliance was monitored by measuring body weight at each visit. Blood samples were taken at the baseline and at 3, 6 and 12 months. The study was a part of a large placebo-controlled multicentre study. 12 Fibrinogen, FVIIc and PAI-1 Venous blood samples were drawn without stasis between 07 30 and 10 00 am after a 12 h fast and a 15-min rest in sitting position. The subjects were advised not to smoke before drawing the blood sample and to avoid strenuous physical activity the day before blood sampling. In the case of any acute infection, blood samples were taken after the symptoms had disappeared and the patient was well. The ®rst 3 ml of blood were not used. Specimens were collected into two 4.5-ml vacuum Becton Dickson siliconated tubes containing 0.5 ml 0.129 M sodium citrate using 0.9Â40 mm needles (type H1004 VMS). Tubes were inverted gently seven times. Specimens were centrifuged at 1400 g for 30 min at room temperature within an hour. Plasma of the two tubes was combined into a G 12.4Â85 mm propylene Mekalasi tube (Milian AIL-137 stopper) and inverted again seven times. After that plasma was divided into seven Eppendorf tubes (0.5 ml each) and immediately frozen in carbonic acid ice. Tubes were stored at À70 C until shipped in batch to the central laboratory in Helsinki. Blood samples were analysed at the Department of Haemostasis at the Finnish Red Cross Blood Transfusion Service. The reference values of ®brinogen and FVIIc were obtained from a plasma pool of 100 blood donors (50 female: 50 male). The reference values of PAI-1 were determined from blood samples of 56 donors. The laboratory reference values were 1.8 ± 4.0 gal for ®brinogen, 63 ± 135% for FVIIc and`23.0 AUaml for PAI-1.
Fibrinogen was measured with ACL coagulometer (Instrumentation Laboratory, Milan, Italy) with the derived method 13 (IL Test 2 PT-Fibrinogen, Instrumentation Laboratory). A single lot of calibration plasma was used as a standard. The interassay precision was 1.9%.
FVIIc was measured with the one-stage method using rabbit brain thromboplastin (Thromboplastin IS, Baxter Diagnostics Inc., Deer®eld, USA) and human immunodepleted FVII-de®cient plasma (Behring, Marburg, Germany). The assays were carried out with ACL coagulometer. A frozen plasma pool of 44 blood donors was taken as 100%. The interassay precision was 2.3%. PAI-1 was measured with a chromogenic method (Coatest 1 PAI, Chromogenix AB, Molndal, Sweden) according to the manufacture. The interassay precision was 5.5%.
Other measurements
Serum insulin was determined by a radioimmunoassay with a double antibody-PEG technique CIS (CIS Biointernational, B.P. 32, F-91192, Git-sur-Yvette Codex, France). Serum and lipoprotein lipids were analysed after ultrasentrifugation and precipitation by enzymatic methods. 14, 15 The CHOD-PAP method was applied for cholesterol and HDL cholesterol and GPO-PAP method for triglycerides.
Weight was measured to the nearest 0.1 kg using an electronic scale (Vogle & Halke, Germany) and height was measured to the nearest 0.1 cm. Bioelectrical impedance (BioElectrical Impedance Analyzer System, RJL Systems, Detroit, MI) was used to measure body fat and fat-free mass.
Blood pressure was measured by the auscultatory method in the sitting position after a 5-min rest using a mercury sphygmomanometer. An average of the two measurements was used as the representative of the patient's blood pressure status.
Weight-change categories
To analyse the effects of speci®c weight-change patterns, the 51 subjects were divided into three categories on the basis of their weight change from 6 to 12 months:
Weight change, blood coagulability and ®brinolysis P Rissanen et al 1. Regainers Ð subjects who regained more than 1% of the body weight (n 18). The mean increase was 2.8 kg (range 0.9 to 6.8 kg). 2. Maintainers Ð women whose weight was within AE 1% of their 6-month weight at 12 months (n 12). The mean change was 0.1 kg (rangeÀ0.7 to 0.6 kg). 3. Weight losers Ð women whose weight was more than 1% smaller at 12 months than at 6 months (n 21). The mean decrease was 3.7 kg (rangeÀ16.2 to 1.2 kg).
Statistical analyses
Statistical analyses were performed with the SPSS for Windows 7.5 (SPSS, Chicago, IL, USA) statistical programme. The results are expressed as mean and standard error of mean with a value P 0.05 as a criterion for statistical signi®cance. Due to skewed distribution, a logarithmic transformation was performed on plasma ®brinogen, insulin and PAI-1 values. A general linear model for repeated measures with the simple contrast was used to determine the differences in ®brinogen, FVIIc, PAI-1 and weight between the placebo and orlistat groups, between smokers and non-smokers, between the interaction of time, placebo and orlistat groups and ®nally between the interaction of time, smokers and nonsmokers. The interaction between the changes in ®brinogen, PAI-1, FVIIc, body weight and orlistat treatment was assessed by stepwise, linear regression analysis. Since neither smoking nor orlistat treatment had a statistically signi®cant effect on the changes in the concentration of ®brinogen, or activities of FVII or PAI-1 the subjects were further analysed as a one group. Differences in groups according to the amount of weight change (%) at 3 months and 12 months were analysed by Wilcoxon-test for two related groups using the exact Monte Carlo test. Bonferroni correction was used for multiple comparison. The Pearson partial correlation coef®cient was used to study the associations between the changes of PAI-1, FVIIc and serum glucose, insulin, lipids and diastolic and systolic blood pressure after adjusting for the body fat mass change (kg) from the baseline. The two-tailed signi®cance was used.
Results
Changes of body weight in orlistat and placebo groups During the 4 week run-in period body weight was reduced on average by 3.3 kg. Although consistently greater in the orlistat group, weight loss of the orlistat and placebo groups did not differ statistically signi®cantly at any time point during the trial. The mean weight losses of the orlistat and placebo groups were, respectively, 9.1 vs 6.3 kg, 11.6 vs 7.5 kg and 13.0 vs 7.2 kg from the baseline to 3, 6 and 12 months.
Changes of haemostatic risk factors in relation to weight loss The average PAI-1 activity declined throughout the study ( Table 1 ). The change in PAI-1 was in¯uenced by weight change but not by orlistat treatment at any time point in stepwise linear regression analysis (data not shown). The standardized b-coef®cient for the change of PAI-1 by weight change was 0.29 (P 0.038) at 3 months, 0.54 (P 0.001) at 6 months and 0.383 (P 0.006) at 12 months. The mean FVIIc declined correlating with weight loss (the standardized b-coef®cient 0.36, P 0.01) during the ®rst 3 months but reached the baseline activity at 12 months (Table  1) . Orlistat did not in¯uence the alteration of FVII activity beyond its effect on weight loss (data not shown).
The relation of weight loss and PAI-1 and FVII activities from the baseline to 3 months is shown in Figure 1 . Women with weight loss less than 5% had an increase in both activities, while greater weight loss decreased the activities.
The concentration of ®brinogen remained unchanged throughout the study (Table 1) .
Changes of haemostatic risk factors in relation to weight loss maintenance and weight regain Between months 6 and 12, 35% of women regained weight, 24% had stable weight (within 1%) and 41% continued to lose weight. The activities of PAI-1 and FVII were raised by an average 14.1% (P b 0.05) and 7.7% (P b 0.05), respectively ( Figure 2 ). The activities remained below the 6 month values if the weight loss was sustained or continued, but only the change of PAI-1 activity with weight loss was statistically signi®cant (P`0.001).
Changes of other cardiovascular risk factors in relation to weight loss, weight loss maintenance and weight regain Diastolic and systolic blood pressure and LDL cholesterol reduced during the ®rst 3 months (Figure 1 ). However, Weight change, blood coagulability and ®brinolysis P Rissanen et al despite a continuous decline of mean weight during 3 ± 12 months, these risk factors showed no further decline or even a rebound rise (Table 2 ). In particular, the mean systolic blood pressure increased signi®cantly (P 0.014) from 6 to 12 months. The levels rose in all women, including those who continued to lose weight (P b 0.05), (Figure 2 ). Changes in serum insulin were similar to those of PAI-1 and FVIIc after 6 months. Weight regainers had increased insulin levels compared to 6-month levels (P`0.001), whereas weight maintainers and losers sustained their serum insulin concentrations below the 6-month levels (P b 0.05).
The associations between changes of PAI-1 and FVII activities with changes of other cardiovascular risk factors We also studied the associations between the changes in PAI-1 and FVII activities with changes of other cardiovascular risk factors including diastolic and systolic blood pressure, serum total and LDL cholesterol, triglycerides and insulin after adjusting for the body fat mass change from the baseline. Most of the associations were weak (data not shown). Signi®cant correlations were detected between the changes of insulin levels and activities of PAI-1 (r 0.34, P 0.015 and r 0.32, P 0.028, respectively, at 6 and 12 months) and FVII (r 0.40, P 0.004 at 6 months). Also the alteration of triglycerides was associated with the change of FVII (r 0.40, P 0.004 and r 0.41, P 0.004, respectively, at 6 and 12 months).
Discussion
In line with earlier reports 7, 8, 11 ,16 the present study shows that the activities of PAI-1 and FVII declined after a modest weight loss in healthy obese women. The new ®nding was that bene®cial changes in ®brinolysis and coagulation persisted for 1 y if weight loss was maintained, whereas even a minor weight regain led to rebound rise of both the activities of PAI-1 and FVII. The alterations of the activities of PAI-1 and FVII correlated with the changes of serum insulin.
While the short-term effects of weight loss on ®brinolysis and coagulation are well documented, 10,17 ± 19 the long-term effects of weight maintenance have seldom been studied. In the study of Svendsen and co-workers, 8 obese women lost an average of 9.6 kg (10% of initial body weight) in 3 months and were encouraged to avoid weight regain thereafter. After an average body weight regain of 2 kg in 6 months, a signi®cant increase in PAI-1 activity was observed. In the study of Marckman and co-workers, 11 obese women lost 12.6 kg in 2 ± 4 months. In the maintenance phase lasting for 6 months, patients gaining some weight (average 0.5 kg) and those who lost further weight (average 2.3 kg) maintained the improved ®brinolysis and coagulation. In a study of Mavri and co-workers, 20 obese women reduced their weight by an average of 14.0 kg in 3 months. After a 5 month follow-up the decreased level of PAI-1 remained low in the women who maintained their reduced weight but increased in the women who regained (average 8.0 kg) weight. The bene®cial effects of weight maintenance and adverse effects of even minor regain after weight loss emphasize the need for effective long-term weight maintenance Figure 1 Changes of activities of plasma PAI-1 and FVII, serum LDL cholesterol, systolic and diastolic blood pressure in relation to percentage weight loss from the baseline to month 3. Values are mean ( AE s.e.m.). *P`0.05; **P`0.01; ***P`0.001.
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We studied the association between the change of the activity of PAI-1 and the change of other cardiovascular risk factors during the weight loss. The strongest correlations were seen with the alterations of serum insulin concentrations. These remained signi®cant even after adjusting for the changes of body fat mass, suggesting an association between the activity of PAI-1 and serum insulin independent of fat mass. Correlations of PAI-1 with fasting insulin concentrations have been reported in population-based studies 21 and with weight reduction. 7 The mechanism behind this association is not precisely known. In vitro, insulin, 22 proinsulin 23 and VLDL 24 have been shown to stimulate PAI-1 production in hepatocytes and in the arterial endothelial cells. 25, 26 However, in vivo studies offer controversial results. Acute administration of insulin or triglycerides has 27, 28 or has not increased PAI-1 activity in human studies. 29 ± 32 Con¯icting results may be due to pooling the results of men and women, small sample sizes, different methods, diverse dosages of insulin and short duration of euglycemic hyperinsulinaemia clamp studies. Contradictionary results may also mean that chronic hyperinsulinaemia but not acute hyperinsulinaemia affect the ®brinolytic system.
Our ®nding that systolic blood pressure tended to increase in all women, even in the absence of weight regain after 6 months, differs from the observations of a previous controlled study. 33 Increased activity of the sympathetic nervous system (SNS) due to hyperinsulinaemia may partly explain the elevated blood pressure in obesity. 34 Weight loss and caloric restriction cause decreased SNS activity and thereby lead to the lowering of blood pressure, 35, 36 but this effect may be only transient.
There are some limitations to our study that should be noted. Seasonal variation may have in¯uenced activities of FVII and PAI-1. In this study this is likely to have a minor effect on the results, since most of the blood samples (baseline, month 12 and 3) were collected in the winter. The ®rst blood samples of FVII, PAI-1 and ®brinogen were drawn after a 1 month run-in period with a mean weight reduction of Weight change, blood coagulability and ®brinolysis P Rissanen et al 3.3 kg, which may have in¯uenced activities of ®brinolysis and coagulation factors at the baseline. However, this is likely to be of minor signi®cance in the women who lost less than 5% of initial body weight at 3 months as their mean weight loss was only 1.8 kg during the run-in period (data not shown). The other women lost more weight during the run-in period and may have had improved ®brinolysis and coagulation already at baseline, which would lead to an underestimation of the true result at 3 months.
In conclusion, the maintenance of modest weight loss is associated with long-term bene®ts for PAI-1 1 and FVII. The concentration of ®brinogen is not affected by modest weight reduction in healthy obese women.
